The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A semi-synthetic triterpenoid drug. It is an Nrf2 activator that is approved for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; [omaveloxolone co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]